Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study
Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study
Enrolling by invitation · NCT07197788 · Registry updated 2026-09-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Enrolling by invitation | Not applicable | 2026-09-24 | NCT07197788 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Endogenex, Inc. | 4 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Baker Heart and Diabetes Institute | Melbourne | Australia | 17 |
| Care Access | Quincy | United States | 2 |
| Care Access | Raleigh | United States | 2 |
| Care Access | Houston | United States | 2 |
| HCA Florida Mercy Hospital | Miami | United States | 7 |
| Houston Methodist | Houston | United States | 63 |
| Orlando Health | Orlando | United States | 64 |
| Robert Wood Johnson Medical School | New Brunswick | United States | 12 |
| St. Vincent's Hospital Melbourne | Fitzroy | Australia | 12 |
| University of Texas at Austin | Austin | United States | 37 |